Inclusion Criteria:

- A female who enrolled in the HPV-012 (NCT00337818) study in Denmark, Estonia and
Finland, received three doses of vaccine and completed Visit 4 (Month 7).

- Written informed consent obtained from the subject prior to enrolment (for subjects
below the legal age of consent, written informed consent must be obtained from a
parent or legally acceptable representative (LAR) and, in addition, the subject must
sign and personally date a written informed assent).

Exclusion criteria

- Use of any investigational or non-registered product (drug or vaccine) or planned use
during the study period.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product (pharmaceutical product or device).

- Chronic administration of immunosuppressants or other immune-modifying drugs
occurring less than three months prior to blood sampling.

- Administration of immunoglobulins and/or any blood products within the three months
preceding blood sampling.